Vaccinex’s Phase Ib/II trial for Alzheimer’s treatment hits primary endpoint

Vaccinex’s Phase Ib/II trial evaluating its Alzheimer’s disease treatment pepinemabin has met its primary endpoint, consolidating previous evidence of the therapy’s neurodegenerative efficacy in Huntingdon’s disease.